

FOI REQUEST NUMBER: 5644

FOI Request re Idiopathic Pulmonary Fibrosis (IPF) Patients

Does your Trust manage/treat patients with Idiopathic Pulmonary Fibrosis (IPF) (ICD-10 J840, J841, J848, J849)?

Yes

No

If No, please go to "IPF Patient Referrals"

If yes, how many patients within your Trust received a diagnosis of IPF (ICD-10 J840, J841, J848, J849) within the last 6 months:

Number of patients diagnosed with IPF within the last 6 months	135
---	-----

This relates to the number of inpatients with IPF, coded in the primary position between 01/05/2017 and 31/10/2017 (Codes: J840, J841, J848, J849). There may also be a number of patients diagnosed with IPF in outpatient clinics, but due to the way data is collated we do not hold this information for outpatients.

Please indicate the number of unique IPF patients managed by your Trust treated with the following:

Therapy	Number of IPF patients treated within the last 30 days	Number of IPF patients treated within the last 3 months
Esbriet (pirfenidone)	30	35
Ofev (nintedanib)	41	50
Any treatment <u>other than</u> Ofev or Esbriet ¹	We do not hold this information in a retrievable format	

If information is held in a sufficient way within your Trust systems, please indicate the total number of current/active IPF patients managed by your Trust, that is, patients that could have received a diagnosis of IPF at any time and are currently receiving anti-fibrotic, other or no treatment for IPF by your Trust. If you do not hold information in this way, please indicate accordingly and proceed to the referrals question:

Number of current/active IPF patients	Data not held/accessible by Trust

¹ Any treatment other than Ofev or Esbriet i.e. patient is not treated with Ofev or Esbriet, but is/has received IPF treated with one or multiple of the following treatments: **Corticosteroids** (prednisone); Immunosuppressants, **Cyclophosphamide** (Cytoxan®); **Azathioprine** (Imuran®); **Mycophenolate mofetil** (Cellcept®, Myfortic®); **N-acetylcysteine** (NAC); **Proton pump inhibitors** (Prilsec OTC®, Nexium®, others); **Supplemental Oxygen Therapy**; **Other** (anti-cough, vaccines etc); **Palliative Care** (morphine)

Total number managed by Trust		X
Treated with anti-fibrotics (Esbriet/Ofev)	71	
Treated with any other treatment <u>excluding</u> Ofev/Esbriet ²		X
Not currently treated ³		X

IPF Patient Referrals

Does your Trust refer IPF patients to other Trusts?	Select all that apply	Trusts to which patients are referred
Yes, all IPF patients referred upon diagnosis		
Yes, when they need treatment with an anti-fibrotic (Esbriet/Ofev)		
No	X	

² As footnote 1

³ Not currently treated – this could be mild IPF patients that do not currently require treatment